A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

NCT07059221 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: SHR-A2102
DRUG: Adebrelimab
DRUG: Cetuximab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.